Across TCGA pan-cancer cohorts, CFAP77 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CFAP77 data layer compared with 22 for mass-spec protein and 1 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CFAP77 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP77 expression acts as an unfavorable survival marker.
LUAD and LSCC are the cancer types where CFAP77 mass-spec protein most reproducibly stratifies survival.